RecruitingPhase 3NCT06525220
A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1)
Studying Squamous cell carcinoma of the hypopharynx
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Merus B.V.
- Intervention
- Petosemtamab(drug)
- Enrollment
- 500 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2024 – 2030
Study locations (30)
- Site 164, Mobile, Alabama, United States
- Site 36, La Jolla, California, United States
- Site 27, Los Angeles, California, United States
- Site 16, Palo Alto, California, United States
- Site 19, Newark, Delaware, United States
- Site 108, Washington D.C., District of Columbia, United States
- Site 14, Fort Myers, Florida, United States
- Site 48, Orlando, Florida, United States
- Site 8, Orlando, Florida, United States
- Site 21, St. Petersburg, Florida, United States
- Site 20, West Palm Beach, Florida, United States
- Site 171, Atlanta, Georgia, United States
- Site 50, Chicago, Illinois, United States
- Site 2, Louisville, Kentucky, United States
- Site 162, Baton Rouge, Louisiana, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06525220 on ClinicalTrials.govOther trials for Squamous cell carcinoma of the hypopharynx
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07063212A Study of Sacituzumab Govitecan in Combination With Cetuximab in People With Head and Neck Squamous Cell Cancer (HNSCC)Memorial Sloan Kettering Cancer Center
- RECRUITINGPHASE1NCT06761937Thermoradiotherapy for Locally Advanced Head and Neck Cancer PatientsErasmus Medical Center
- RECRUITINGPHASE3NCT06706401Lymphocyte-Sparing And Radio-Immunotherapy in Head and Neck CarcinomaCentre Leon Berard
- RECRUITINGNCT06380686Head and Neck Carcinoma Clinical Research Platform for Molecular and Blood-based Biomarkers, Treatment and OutcomeAIO-Studien-gGmbH
- RECRUITINGPHASE3NCT05333523Personalized Elective Neck Irradiation Guided by Sentinel Lymph Node Biopsy in Larynx and Pharynx Cancer. The PRIMO Study.Radboud University Medical Center
- RECRUITINGPHASE2NCT04858269First Line Weekly Chemo/Immunotherapy for Metastatic Head/Neck Squamous Cell Carcinoma PatientsWake Forest University Health Sciences
- ACTIVE NOT RECRUITINGPHASE3NCT04590963Assessment of Efficacy and Safety of Monalizumab Plus Cetuximab Compared to Placebo Plus Cetuximab in Recurrent or Metastatic Head and Neck CancerAstraZeneca
- RECRUITINGPHASE2, PHASE3NCT01810913Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck CancerNational Cancer Institute (NCI)
See all trials for Squamous cell carcinoma of the hypopharynx →